Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18713672 | 0.92 | PTGS2 (0.37) | PTGS2PTGS1CRHR1LMNAALDH1A1 | |
| SCHEMBL20032375 | 0.89 | TRPV1 (0.36) | PTGS2PTGS1CRHR1LMNACNR1 | |
| SCHEMBL20032482 | 0.88 | TRPV1 (0.36) | CNR1CYP1A2HTR2ASLC6A4KCNH2 | |
| SCHEMBL21366762 | 0.85 | PSEN1 (0.39) | LMNACNR1ALDH1A1HTTHTR2A | |
| SCHEMBL20032447 | 0.82 | AKR1C3 (0.39) | LMNA | |
| SCHEMBL18713796 | 0.81 | KCNH2 (0.36) | CRHR1LMNACNR1ALDH1A1CYP3A4 | |
| SCHEMBL21366928 | 0.81 | KCNH2 (0.43) | PTGS2CNR1TP53KCNH2 | |
| SCHEMBL20032371 | 0.81 | KCNH2 (0.40) | PTGS2PTGS1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL20032433 | 0.80 | PTGDR2 (0.38) | — | |
| SCHEMBL18713639 | 0.80 | TRPV1 (0.38) | PTGS2PTGS1CRHR1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | PTGS2 645/4885PTGS1 125/4885CRHR1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.